Drug Profile
Research programme: BET bromodomain inhibitors - ConverGene
Alternative Names: CN 470; CVG201 programmeLatest Information Update: 28 Jan 2021
Price :
$50
*
At a glance
- Originator ConverGene; National Center for Advancing Translational Sciences
- Class Antineoplastics; Small molecules
- Mechanism of Action Bromodomain and extraterminal domain protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Precursor cell lymphoblastic leukaemia-lymphoma
- No development reported Cancer
Most Recent Events
- 28 Jan 2021 No recent reports of development identified for preclinical development in Cancer in USA (PO)
- 22 Jun 2020 Pharmacodynamics data from a preclinical study in Precursor cell lymphoblastic leukaemia-lymphoma presented at the 111th Annual Meeting of the American Association for Cancer Research - II (AACR-II-2020)
- 20 Jun 2020 Preclinical trials in Precursor cell lymphoblastic leukaemia-lymphoma in USA (PO) prior to June 2020